Breaking News, Collaborations & Alliances

Alexion, Moderna Enter Exclusive Messenger RNA Pact

To develop therapeutics for rare diseases

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Alexion Pharmaceuticals and Moderna Therapeutics have entered an exclusive strategic agreement for the discovery and development of messenger RNA Therapeutics to treat rare diseases. Messenger RNA Therapeutics are designed to use the body’s natural processes to enable the in vivo production of both intracellular proteins and secreted proteins, which act to restore function elsewhere in the body. The mRNA Therapeutics platform has the potential to speed the development and manufacture of treatmen...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters